- Home
- VCNX vs VLCN Comparison
VCNX vs VLCN Comparison
Compare VCNX & VLCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VCNX
- VLCN
- Stock Information
- Founded
- VCNX 2001
- VLCN 2020
- Country
- VCNX United States
- VLCN United States
- Employees
- VCNX N/A
- VLCN N/A
- Industry
- VCNX Biotechnology: Pharmaceutical Preparations
- VLCN Auto Manufacturing
- Sector
- VCNX Health Care
- VLCN Consumer Discretionary
- Exchange
- VCNX Nasdaq
- VLCN Nasdaq
- Market Cap
- VCNX 4.5M
- VLCN 4.5M
- IPO Year
- VCNX N/A
- VLCN 2021
- Fundamental
- Price
- VCNX $3.22
- VLCN $4.00
- Analyst Decision
- VCNX
- VLCN
- Analyst Count
- VCNX 0
- VLCN 0
- Target Price
- VCNX N/A
- VLCN N/A
- AVG Volume (30 Days)
- VCNX 167.3K
- VLCN 46.8K
- Earning Date
- VCNX 11-29-2024
- VLCN 11-12-2024
- Dividend Yield
- VCNX N/A
- VLCN N/A
- EPS Growth
- VCNX N/A
- VLCN N/A
- EPS
- VCNX N/A
- VLCN N/A
- Revenue
- VCNX $388,000.00
- VLCN $4,134,075.00
- Revenue This Year
- VCNX N/A
- VLCN $339.16
- Revenue Next Year
- VCNX N/A
- VLCN N/A
- P/E Ratio
- VCNX N/A
- VLCN N/A
- Revenue Growth
- VCNX N/A
- VLCN 41.15
- 52 Week Low
- VCNX $1.39
- VLCN $3.95
- 52 Week High
- VCNX $13.02
- VLCN $8,640.00
- Technical
- Relative Strength Index (RSI)
- VCNX 48.87
- VLCN 27.86
- Support Level
- VCNX $2.87
- VLCN $5.13
- Resistance Level
- VCNX $3.43
- VLCN $7.15
- Average True Range (ATR)
- VCNX 0.53
- VLCN 0.73
- MACD
- VCNX 0.05
- VLCN -0.10
- Stochastic Oscillator
- VCNX 23.22
- VLCN 1.72
About VCNX Vaccinex Inc.
Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.
About VLCN Volcon Inc. Common stock
Volcon Inc is an all-electric, off-road powersports vehicle company developing and building electric two and four-wheel motorcycles and utility terrain vehicles, also known as side-by-sides, along with a complete line of upgrades and accessories. The company's products include motorcycle and UTV products that are all-electric and designed for off-road use. The company has hundred and three dealers covering twenty eight states.